Trump announces Regeneron drug deal

Regeneron has become the 17th major drugmaker to reach a pricing agreement with the Trump administration.

The deal includes a significant price reduction for a widely used cholesterol drug and the provision of a newly approved gene therapy for genetic deafness at no cost to eligible patients.

Trump hailed the agreement as the 'biggest price reduction in drugs in history,' positioning it as a key economic relief measure ahead of the midterm elections.

Critics, however, have questioned the long-term sustainability of such voluntary agreements and their impact on future pharmaceutical innovation.